Martínez OJL, González TH, Pereyra RJL, Carballo FC

Language: Spanish
References: 5
Page: 9-19
PDF size: 227.85 Kb.

ABSTRACT

Background. Sleep impairness is one of the most common diseases in children behavior. Between 25 up to 46% of children could present some kind of sleep impairness, which could be related to other medical conditions or conduct problems. Awakenings during night affect up to 42% of population, problems related to sleep onset and it’s maintenance affect between 10 and 20%, daytime sleepiness a 10% and respiratory problems related to sleep time between 1 and 3%. There are some acute and chronic diseases which have an impact on sleep, like nasal congestion, adenoid hypertrophy, otitis, asthma, reflux esophagitis and some neurologic diseases. Primary sleep impairness could present as attention deficit disorder, so it is important to make an accurate diagnosis and assess the need to initiate joint treatment for both diseases. Objective. The aim of this study was to determine the efficacy of magnesium glutamate hydrobromide (MGB) in sleep impairness in children between 4 and 6 years, compared with placebo, during a 6 months period. Method. We performed an experimental, observational, comparative, prospective study. Forty five children with sleep impairness where enrolled. We divided the sample in three groups; 15 children treated with placebo, 15 children treated with MGB and in the third group we enrolled children with sleep impairness and attention deficit disorder, also treated with MGB (plus their attention deficit disorder medication). Results. Children with sleep impairness in which no MGB was used within 6 months of treatment had 4 times more sleep disruptions per month and twice sleeptime disturbances per month in relation to those treated with MGB. Conclusions. BGM treated children had a better outcome in their sleep impairness demonstrated by the percentages of less arousals and more continuous sleep, compared with patients treated with placebo. There were no significative differences when the groups were compared with the attention deficit disorder group. This study showed that MGB is a useful drug for sleep disorders in children between 4 and 6 years old. More research is needed in patients with attention deficit disorder to have accurate conclusions.

REFERENCES

1. Tomás M, Miralles A, Beseler B, Revert M, Sala M, Uribelarrea A. Relación entre el trastorno por déficit de atención e hiper-actividad y los trastornos del sueño. Resultados de un estudio epidemiológico en la población escolar de la ciudad de Gandía. Anales de Pediatría 2008; 69 (3): 251-7.

2. Tomás M, Miralles A, Beseler B. Versión española del Pediatric Sleep Questionnaire. Un instrumento útil en la investigación de los trastornos del sueño en la infancia. Análisis de su fiabilidad. Anales de Pediatría 2007; 66 (2): 121-8.

3. Suárez A, Robles B. Hábitos de sueño en la revisión del niño sano. Boletín de Pediatría 2005; 45: 17-22.

4. Daniel W. Bioestadística. Bases para el análisis de las ciencias en la salud. Cuarta edición. Editorial Limusa Wiley. México, 2006.

5. Morgenthaler T, Owens J, Alessi C, Boehlecke B, Brown T, Coleman J et al. Practice parameters for behavioral treatment of bedtime problems and night waking in infants and young children. Sleep 2006; 29 (20): 1277-1281.